City of Hope | Institution Partners

When cancer harms the body’s ability to make antibodies, what does that mean for the efficacy of vaccines?

From the use of BTK inhibitors to maintenance therapy, an expert highlights how the treatment landscape of mantle cell lymphoma has drastically changed for the better in recent decades.

A blood cancer specialist discusses how the development of tyrosine kinase inhibitors in the 1990s to treat chronic myelogenous leukemia drove major oncology advancements over the next three decades.

When cancer treatments stop working, it is not the end of the line. Most patients with advanced disease will be on continuous therapy, and that means trying different options along the way.